TRANSGENE SIGNS AGREEMENT FOR THE PRODUCTION OF INNOGENETICS' HEPATITIS B THERAPEUTIC VACCINE CANDIDATE

Transgene S.A., Strasbourg, France (Eurolist Paris: FR0005175080) today announced that it has signed a manufacturing agreement with Innogenetics, a biotechnology company located in Gent, Belgium, to produce Innogenetics' clinical-grade Hepatitis B therapeutic vaccine candidate. Transgene will be paid a fixed total amount, with installments made at specified times over the life of the contract. The vaccine construct has been developed by Transgene under a previous service agreement with Innogenetics. It uses the MVA (Modified Vaccinia Ankara) vector technology to express polyepitopes of the hepatitis B virus.

Euronext (http://www.euronext.com/news/companypressrelease/0,4616,1700631_11894_666283763,00.html)